Details

Autor(en) / Beteiligte

• Serrano-Mayorga, Cristian C.
• Ibáñez-Prada, Elsa D.
• Restrepo-Martínez, Juan M.
• Garcia-Gallo, Esteban
• Duque, Sara
• Severiche-Bueno, David Felipe
• Severiche-Bueno, Diego Fernando
• Gomez, Sandra
• Vargas, Hernán
• Reyes, Luis Felipe

Titel

The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia

Ist Teil von

• Vaccine, 2024-03, Vol.42 (7), p.1435-1439

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• To provide information about which pneumococcal vaccine could have greater coverage in Colombia. This is a retrospective analysis of patients diagnosed with invasive pneumococcal disease (IPD) between 2015 and 2019 in Bogotá, Colombia. We compared the theoretical serotype coverage of the available anti-pneumococcal vaccines (i.e., PCV-10, PCV-10 SII, PCV-13, PCV-15, PCV-20, PCV-21, PCV24, PPSV-23) and the non-vaccine-covered serotypes stratified by age. 690 IPD cases were included. In children ≤5 y/o, of the approved vaccines PCV-20 showed the most theoretical protection (71.3 % [149/209]), while in adults aged 18–64 y/o was PCV-20 (61.8 % [164/265]), and in those ≥65 y/o was PPSV-23 (58.1 % [100/172]) followed by PCV-20 (55.2 % [95/172]). The non-covered serotypes represented one-third of the cohort (33.9 % [234/690]), being 6C (20.5 % [48/234]), 15A (12.8 % [30/234]), and 23A (11.5 % [27/234]) the most prevalent. Introducing PCV-20 for children and PCV-20 along with a PPSV-23 booster in adults may reduce IPD frequency in all ages in Colombia. The inclusion of non-covered serotypes is required for future vaccines.